Having observed the pro-metastatic effects of NaV1.5 and knowing that inhibitors of NaV1.5 are seen as emerging therapeutic candidates for breast cancer, Wu and colleagues conducted tests to analyze the potential of the peptide as an inhibitor of this channel in triple-negative breast cancer cells (Luo et al., 2020; Wu et al., 2023). This evidence concerns the gene SCN5A and breast carcinoma.